NCAM1 and acute lymphoblastic leukemia: Recently, antibody-based anticancer treatment was analyzed with the expression levels of NCAM1. The phase 1/2 study is ongoing, since NCAM1 is expressed on several malignancies, including SCLC [58,59,60], or could be available to predict prognosis in adult acute lymphoblastic leukemia patient [61].